-+ 0.00%
-+ 0.00%
-+ 0.00%

CervoMed plans neflamapimod 100 mg twice-daily regimen for future clinical trials

PUBT·09/28/2026 11:32:15
Listen to the news
CervoMed plans neflamapimod 100 mg twice-daily regimen for future clinical trials
  • CervoMed disclosed Phase 1 study results for a new neflamapimod 50 mg tablet, positioning it for twice-daily dosing.
  • The new formulation is intended to deliver steadier drug levels while reducing dosing frequency, addressing variability seen with the prior capsule.
  • FDA lifted a prior plasma exposure cap, removing a key constraint on dose escalation in upcoming trials.
  • Future clinical trials are planned to test a 100 mg twice-daily regimen, aiming for stronger expected activity with manageable tolerability.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280730PRIMZONEFULLFEED9834644) on September 28, 2026, and is solely responsible for the information contained therein.